Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
Anemia is a major complication of end-stage kidney disease (ESKD). Erythropoiesis-stimulating agents and intravenous (IV) iron are the current backbone of anemia treatment in ESKD. Iron overload induced by IV iron is a potential clinical problem in dialysis patients. We compared the pharmacokinetics...
Main Authors: | Guy Rostoker, Fanny Lepeytre, Myriam Merzoug, Mireille Griuncelli, Christelle Loridon, Ghada Boulahia, Yves Cohen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/7/1408 |
Similar Items
-
Parenteral Iron Therapy for Pediatric Patients
by: Elpis Mantadakis, et al.
Published: (2024-01-01) -
A comparative study of ferric carboxymaltose and iron sucrose as a parenteral iron treatment in iron deficiency anemia during pregnancy in a tertiary care hospital
by: Sandip Kumar Ghosh, et al.
Published: (2024-04-01) -
Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long‐term study
by: Tilmann Kramer, et al.
Published: (2021-12-01) -
Does Repeated Dosing of Intravenous Ferric Carboxymaltose Alleviate Symptoms of Restless Legs Syndrome?
by: Hea Ree Park, et al.
Published: (2022-03-01) -
Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience
by: Esra TERZİ DEMİRSOY
Published: (2021-08-01)